Ivastine

Rivastigmine, the active ingredient in Ivastine, is a cholinesterase inhibitor presented as a transdermal patch for transdermal use. It is indicated for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease dementia in adult patients, helping to improve cognitive function and daily activities.

GNH USA supplies Ivastine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory‑approved batches to meet global demand. Logistics are managed with temperature‑controlled shipping where required, ensuring product integrity from manufacture to delivery.

Rivastigmine, marketed as Ivastine, is used in the management of dementia‑related conditions by enhancing cholinergic neurotransmission.

Alzheimer’s disease: improves cognition and functional abilities in mild to moderate stages. Parkinson’s disease dementia: helps mitigate cognitive decline associated with Parkinson’s disease. Mild to moderate dementia: provides symptomatic relief of memory and attention deficits.

Rivastigmine transdermal therapy may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Skin irritation at the application site - Nausea - Vomiting - Diarrhea - Dizziness

Serious or Rare Side Effects: - Severe skin reactions such as rash or bullous dermatitis - Bradycardia or syncope - Gastrointestinal bleeding or ulceration

When prescribing Ivastine, clinicians should consider several precautionary measures to ensure safe use.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: use with caution in patients with liver disease. Cardiovascular disease: observe for bradycardia or syncope. Gastrointestinal disorders: assess risk of nausea, vomiting, or ulceration. Skin application site: rotate patch locations to minimize irritation. Store at room temperature: keep in original packaging, protect from moisture and direct heat.

Rivastigmine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticholinergic drugs: reduce therapeutic effect of rivastigmine. - Concurrent use of other cholinesterase inhibitors: increase risk of cholinergic toxicity. - Beta‑blockers: may exacerbate bradycardia when combined.

Moderate Interactions (Monitor Closely): - SSRIs or other antidepressants: may increase nausea or gastrointestinal upset. - Antihypertensive agents: potential additive hypotensive effect. - CYP3A4 inhibitors or inducers (e.g., ketoconazole, rifampicin): may modify rivastigmine plasma concentrations.